HC Wainwright Reiterates "Buy" Rating for Cartesian Therapeu

HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $54.00 target price on the stock. A number of other research firms have also issued reports on RNAC. Needham & Company LLC reaffirmed a buy rating and […]

Related Keywords

United States , American , Leerink Partnrs , Hall Laurie , Timothya Springer , Securities Exchange Commission , American International Group Inc , Delphi Financial Group Inc , Needham Company , Cartesian Therapeutics Inc , Sg Americas Securities , Cartesian Therapeutics , Free Report , Therapeutics Stock Down , Get Free Report , Director Timothy , Exchange Commission , Lauriej Trustee , International Group , Financial Markets , Delphi Financial Group , Cartesian Therapeutics Daily ,